Literature DB >> 11111455

Chronic lymphocytic leukemia and its impact on the immune system.

D Goldman1.   

Abstract

Myelosuppression and immunosuppression are terms that often are used interchangeably, yet they have very different meanings. Myelosuppression, which is caused by many types of cancer treatments (e.g., chemotherapy, radiation therapy), occurs when the body's population of blood cells is lowered. In contrast, immunosuppression occurs when the body's immune function is compromised. Diseases of either the B or T lymphocytes (e.g., lymphoma, multiple myeloma, CLL) alter the normal functioning of the lymphocytes, rendering them unable to mount an immune response. With CLL, B lymphocytes are unable to mature into immunoglobulin-producing plasma cells (delGiglio et al., 1993). Multiple myeloma occurs when the plasma cells become malignant (Mansen et al., 1997). Knowledge of the basic principles of immunology assists nurses in understanding the complexities of the immune system and the effects of common cancer treatments. Patients with CLL require astute assessment of infectious symptoms, comprehensive nursing care and symptom management, and education about the disease and its effects. Hays and McCartney (1998) also noted that the challenges of caring for patients with CLL include patient management in the outpatient setting, quality-of-life issues, and ongoing support because of the chronicity of the disease.

Entities:  

Mesh:

Year:  2000        PMID: 11111455

Source DB:  PubMed          Journal:  Clin J Oncol Nurs        ISSN: 1092-1095            Impact factor:   1.027


  4 in total

Review 1.  P66Shc: A Pleiotropic Regulator of B Cell Trafficking and a Gatekeeper in Chronic Lymphocytic Leukemia.

Authors:  Laura Patrussi; Nagaja Capitani; Cosima T Baldari
Journal:  Cancers (Basel)       Date:  2020-04-19       Impact factor: 6.639

2.  Chronic lymphocytic leukemia B-cell-derived TNFα impairs bone marrow myelopoiesis.

Authors:  Bryce A Manso; Jordan E Krull; Kimberly A Gwin; Petra K Lothert; Baustin M Welch; Anne J Novak; Sameer A Parikh; Neil E Kay; Kay L Medina
Journal:  iScience       Date:  2020-12-26

3.  The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression.

Authors:  Lisa Rohrbacher; Bettina Brauchle; Ana Ogrinc Wagner; Michael von Bergwelt-Baildon; Veit L Bücklein; Marion Subklewe
Journal:  Front Immunol       Date:  2021-03-15       Impact factor: 7.561

Review 4.  The Newly Identified T Helper 22 Cells Lodge in Leukemia.

Authors:  Gholamreza Azizi; Mohsen Rastegar Pouyani; Shadi Sadat Navabi; Reza Yazdani; Fatemeh Kiaee; Abbas Mirshafiey
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-07-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.